Skip to Main Content

Vedanta Biosciences is touting positive new Phase 2 results for a microbe-based treatment for C. difficile, the fourth major biotech to take this approach toward the life-threatening bacterial disease.

People who received a relatively high dose of Vedanta’s drug, which is made from eight strains of bacteria, had 80% fewer recurrences of C. diff than people who received a placebo, the company said Tuesday. The absolute difference in the proportion of people whose C. difficile infections recurred was more than 37 percentage points.


Vedanta’s executives say the data could make the company’s product the best in its class — and that the approach could give Vedanta another important edge. Unlike the handful of other microbiome therapeutics, Vedanta’s drug — VE303 — is not made from processed, donated stool. Instead, it’s grown from cell banks of specific bacterial species.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.